Extensive gene amplification as a mechanism for piperacillin- Tazobactam resistance in Escherichia coli

mBio

Volumn 9, Issue 2, 2018, Pages

  Schechter, Lisa M ^a   Creely, David P ^a   Garner, Cherilyn D ^a,c   Shortridge, Dee ^a,d   Nguyen, Hoan ^b   Chen, Lei ^b,e   Hanson, Blake M ^b,f   Sodergren, Erica ^b   Weinstock, George M ^b   Dunne, W Michael ^a   van Belkum, Alex ^a   Leopold, Shana R ^b  

^a BIOMÉRIEUX   (France)

^b JACKSON LABORATORY   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d JMI LABORATORIES   (United States)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antibiotic resistance; Escherichia coli; Gene amplification; Piperacillin tazobactam; TEM 1

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE TEM 1; OUTER MEMBRANE PROTEIN C; OUTER MEMBRANE PROTEIN F; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; BETA-LACTAMASE TEM-1;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BROTH DILUTION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; COPY NUMBER VARIATION; DISK DIFFUSION; ESCHERICHIA COLI; GENE AMPLIFICATION; GENE INACTIVATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; WHOLE GENOME SEQUENCING; BETA-LACTAM RESISTANCE; DRUG EFFECT; ENZYMOLOGY; ESCHERICHIA COLI INFECTION; GENE DOSAGE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHARMACOKINETICS;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

EID: 85046443557     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00583-18     Document Type: Article

References (54)

1. Drawz SM, Bonomo RA. 2010. Three decades of β-lactamase inhibitors. Clin Microbiol Rev 23:160-201. https://doi.org/10.1128/CMR.00037-09.
2. Li XZ, Plésiat P, Nikaido H. 2015. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev 28:337-418. https://doi.org/10.1128/CMR.00117-14.
3. Bonomo RA. 2017. β-lactamases: a focus on current challenges. Cold Spring Harb Perspect Med 7:a025239. https://doi.org/10.1101/cshperspect.a025239.
4. Bush K, Jacoby GA. 2010. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 54:969-976. https://doi.org/10.1128/AAC.01009-09.
5. Bush K, Jacoby GA, Medeiros AA. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39:1211-1233. https://doi.org/10.1128/ AAC.39.6.1211.
6. Ambler RP. 1980. The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 289:321-331. https://doi.org/10.1098/rstb.1980.0049.
7. Datta N, Kontomichalou P. 1965. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature 208:239-241. https:// doi.org/10.1038/208239a0.
8. Heffron F, Sublett R, Hedges RW, Jacob A, Falkow S. 1975. Origin of the TEM beta-lactamase gene found on plasmids. J Bacteriol 122:250-256.
9. Bidet P, Basmaci R, Guglielmini J, Doit C, Jost C, Birgy A, Bonacorsi S. 2016. Genome analysis of Kingella kingae strain KWG1 reveals how a β-lactamase gene inserted in the chromosome of this species. Antimicrob Agents Chemother 60:703-708. https://doi.org/10.1128/AAC.02192-15.
10. Lescat M, Calteau A, Hoede C, Barbe V, Touchon M, Rocha E, Tenaillon O, Médigue C, Johnson JR, Denamur E. 2009. A module located at a chromosomal integration hot spot is responsible for the multidrug resistance of a reference strain from Escherichia coli clonal group A. Antimicrob Agents Chemother 53:2283-2288. https://doi.org/10.1128/ AAC.00123-09.
11. Wu PJ, Shannon K, Phillips I. 1994. Effect of hyperproduction of TEM-1β-lactamase on in vitro susceptibility of Escherichia coli to beta-lactam antibiotics. Antimicrob Agents Chemother 38:494-498. https://doi.org/ 10.1128/AAC.38.3.494.
12. Wu PJ, Shannon K, Phillips I. 1995. Mechanisms of hyperproduction of TEM-1 β-lactamase by clinical isolates of Escherichia coli. J Antimicrob Chemother 36:927-939. https://doi.org/10.1093/jac/36.6.927.
13. Shannon K, Williams H, King A, Phillips I. 1990. Hyperproduction of TEM-1 β-lactamase in clinical isolates of Escherichia coli serotype O15. FEMS Microbiol Lett 55:319-323.
14. Stapleton P, Wu PJ, King A, Shannon K, French G, Phillips I. 1995. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother 39:2478-2483. https://doi.org/10.1128/AAC.39.11.2478.
15. Seetulsingh PS, Hall LM, Livermore DM. 1991. Activity of clavulanate combinations against TEM-1 β-lactamase-producing Escherichia coli isolates obtained in 1982 and 1989. J Antimicrob Chemother 27:749-759. https://doi.org/10.1093/jac/27.6.749.
16. Martinez JL, Cercenado E, Rodriguez-Creixems M, Vincente-Perez MF, Delgado-Iribarren A, Baquero F. 1987. Resistance to β-lactam/ clavulanate. Lancet ii:1473.
17. Waltner-Toews RI, Paterson DL, Qureshi ZA, Sidjabat HE, Adams-Haduch JM, Shutt KA, Jones M, Tian GB, Pasculle AW, Doi Y. 2011. Clinical characteristics of bloodstream infections due to ampicillin-sulbactamresistant, non-extended-spectrum β-lactamase-producing Escherichia coli and the role of TEM-1 hyperproduction. Antimicrob Agents Chemother 55:495-501. https://doi.org/10.1128/AAC.00797-10.
18. Sun J, Wang Y, Ni Y. 2013. Hyperproduction of TEM-1 β-lactamase mediates the resistance of Escherichia coli to piperacillin-tazobactam and cefoperazone. Chin J Infect Chemother 13:167-172.
19. Sanders CC, Iaconis JP, Bodey GP, Samonis G. 1988. Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 β-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob Agents Chemother 32:1365-1369. https://doi.org/10.1128/ AAC.32.9.1365.
20. Pérez-Moreno MO, Pérez-Moreno M, Carulla M, Rubio C, Jardí AM, Zaragoza J. 2004. Mechanisms of reduced susceptibility to amoxycillinclavulanic acid in Escherichia coli strains from the health region of Tortosa (Catalonia, Spain). Clin Microbiol Infect 10:234-241. https://doi.org/10.1111/j.1198-743X.2004.00766.x.
21. TEM genes and their relationship to β-lactam resistance. Antimicrob Agents Chemother 46:4035-4037. https://doi.org/10.1128/AAC.46.12.4035-4037.2002.
22. Martinez JL, Vicente MF, Delgado-Iribarren A, Perez-Diaz JC, Baquero F. 1989. Small plasmids are involved in amoxicillin-clavulanate resistance in Escherichia coli. Antimicrob Agents Chemother 33:595. https://doi.org/ 10.1128/AAC.33.4.595-a.
23. San Millan A, Escudero JA, Gifford DR, Mazel D, MacLean RC. 2016. Multicopy plasmids potentiate the evolution of antibiotic resistance in bacteria. Nat Ecol Evol 1:10. https://doi.org/10.1038/s41559-016-0010.
24. Creely D, Zambardi G, van Belkum A, Dunne WM, Jr, Peyret M, Gayral JP, Shortridge D, Shubert C. 2013. International dissemination of Escherichia coli strains with discrepant behaviour in phenotypic antimicrobial susceptibility tests. Eur J Clin Microbiol Infect Dis 32:997-1002. https://doi.org/10.1007/s10096-013-1837-5.
25. Shubert C, Slaughter J, Creely D, van Belkum A, Gayral JP, Dunne WM, Zambardi G, Shortridge D. 2014. Population analysis of Escherichia coli isolates with discordant resistance levels by piperacillin-tazobactam broth microdilution and agar dilution testing. Antimicrob Agents Chemother 58:1779-1781. https://doi.org/10.1128/AAC.02181-13.
26. CLSI. 2017. Performance standards for antimicrobial susceptibility testing, 27th ed. Supplement M100. CLSI, Wayne, P.A.
27. Touchon M, Hoede C, Tenaillon O, Barbe V, Baeriswyl S, Bidet P, Bingen E, Bonacorsi S, Bouchier C, Bouvet O, Calteau A, Chiapello H, Clermont O, Cruveiller S, Danchin A, Diard M, Dossat C, Karoui ME, Frapy E, Garry L, Ghigo JM, Gilles AM, Johnson J, Le Bouguénec C, Lescat M, Mangenot S, Martinez-Jéhanne V, Matic I, Nassif X, Oztas S, Petit MA, Pichon C, Rouy Z, Ruf CS, Schneider D, Tourret J, Vacherie B, Vallenet D, Médigue C, Rocha EP, Denamur E. 2009. Organised genome dynamics in the Escherichia coli species results in highly diverse adaptive paths. PLoS Genet 5:e1000344. https://doi.org/10.1371/journal.pgen.1000344.
28. Firth N, Ippen-Ihler K, Skurray R. 1996. Structure and function of the F factor and mechanism of conjugation. In Neidhardt F, Curtiss R, III, Ingraham JL, Lin ECC, Low KB, Magasanik B, Reznikoff WS, Riley M, Schaechter M, Umbarger HE (ed), Escherichia coli and Salmonella: cellular and molecular biology, 2nd ed. ASM Press, Washington, D.C.
29. Reguera JA, Baquero F, Pérez-Díaz JC, Martínez JL. 1991. Factors determining resistance to β-lactam combined with β-lactamase inhibitors in Escherichia coli. J Antimicrob Chemother 27:569-575. https://doi.org/10.1093/jac/27.5.569.
30. TEM-1 variants: their role in beta-lactam resistance in Klebsiella pneumoniae. J Antimicrob Chemother 52:899-903. https://doi.org/10.1093/jac/dkg486.
31. Beceiro A, Maharjan S, Gaulton T, Doumith M, Soares NC, Dhanji H, Warner M, Doyle M, Hickey M, Downie G, Bou G, Livermore DM, Woodford N. 2011. False extended-spectrum β-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins. J Antimicrob Chemother 66:2006-2010. https://doi.org/10.1093/jac/dkr265.
32. Sun S, Berg OG, Roth JR, Andersson DI. 2009. Contribution of gene amplification to evolution of increased antibiotic resistance in Salmonella typhimurium. Genetics 182:1183-1195. https://doi.org/10.1534/ genetics.109.103028.
33. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D, Chamberland S, Renau T, Leger R, Hecker S, Watkins W, Hoshino K, Ishida H, Lee VJ. 2001. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 45:105-116. https://doi.org/10.1128/AAC.45.1.105-116.2001.
34. Renau TE, Léger R, Flamme EM, Sangalang J, She MW, Yen R, Gannon CL, Griffith D, Chamberland S, Lomovskaya O, Hecker SJ, Lee VJ, Ohta T, Nakayama K. 1999. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J Med Chem 42:4928-4931. https://doi.org/10.1021/jm9904598.
35. Sandegren L, Andersson DI. 2009. Bacterial gene amplification: implications for the evolution of antibiotic resistance. Nat Rev Microbiol 7:578-588. https://doi.org/10.1038/nrmicro2174.
36. McGann P, Courvalin P, Snesrud E, Clifford RJ, Yoon EJ, Onmus-Leone F, Ong AC, Kwak YI, Grillot-Courvalin C, Lesho E, Waterman PE. 2014. Amplification of aminoglycoside resistance gene aphA1 in Acinetobacter baumannii results in tobramycin therapy failure. mBio 5:e00915. https:// doi.org/10.1128/mBio.00915-14.
37. Gallagher LA, Coughlan S, Black NS, Lalor P, Waters EM, Wee B, Watson M, Downing T, Fitzgerald JR, Fleming GTA, O’Gara JP. 2017. Tandem amplification of the staphylococcal cassette chromosome mec element can drive high-level methicillin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 61:e00869-17. https:// doi.org/10.1128/AAC.00869-17.
38. OXA-58 carbapenemase gene in a Proteus mirabilis clinical isolate. Antimicrob Agents Chemother 61:e01697-16. https://doi.org/10.1128/ AAC.01697-16.
39. Livermore DM, Seetulsingh P. 1991. Susceptibility of Escherichia coli isolates with TEM-1 β-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxicillin. J Antimicrob Chemother 27:761-767. https://doi.org/10.1093/jac/27.6.761.
40. Monogue ML, Nicolau DP. 2016. In vitro-in vivo discordance with humanized piperacillin-tazobactam exposures against piperacillintazobactam-resistant/pan-β-lactam-susceptible Escherichia coli. Antimicrob Agents Chemother 60:7527-7529. https://doi.org/10.1128/AAC.01208-16.
41. Stainton SM, Monogue ML, Nicolau DP. 2017. In vitro-in vivo discordance with humanized piperacillin-tazobactam exposures against piperacillintazobactam-resistant/pan-β-lactam-susceptible Klebsiella pneumoniae strains. Antimicrob Agents Chemother 61:e00491-17. https://doi.org/10.1128/AAC.00491-17.
42. Shelburne SA, Kim J, Munita JM, Sahasrabhojane P, Shields RK, Press EG, Li X, Arias CA, Cantarel B, Jiang Y, Kim MS, Aitken SL, Greenberg DE. 2017. Whole genome sequencing accurately identifies resistance to extended spectrum β-lactams for major Gram-negative bacterial pathogens. Clin Infect Dis 65:738-745. https://doi.org/10.1093/cid/cix417.
43. CLSI. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-tenth edition. CLSI document M07-A10. CLSI, Wayne, P.A.
44. Benov L, Al-Ibraheem J. 2002. Disrupting Escherichia coli: a comparison of methods. J Biochem Mol Biol 35:428-431. https://doi.org/10.5483/ BMBRep.2002.35.4.428.
45. Steingrube VA, Wallace RJ, Jr, Brown BA, Pang Y, Zeluff B, Steele LC, Zhang Y. 1991. Acquired resistance of Nocardia brasiliensis to clavulanic acid related to a change in β-lactamase following therapy with amoxicillin-clavulanic acid. Antimicrob Agents Chemother 35:524-528. https://doi.org/10.1128/AAC.35.3.524.
46. Innis M, Gelfand D, Sninsky J, White T. 1990. PCR protocols: a guide to methods and applications. Academic Press, London, United Kingdom.
47. Lee C, Kim J, Shin SG, Hwang S. 2006. Absolute and relative QPCR quantification of plasmid copy number in Escherichia coli. J Biotechnol 123:273-280. https://doi.org/10.1016/j.jbiotec.2005.11.014.
48. Loman NJ, Quinlan AR. 2014. poretools: a toolkit for analyzing nanopore sequence data. Bioinformatics 30:3399-3401. https://doi.org/10.1093/ bioinformatics/btu555.
49. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455-477. https://doi.org/10.1089/cmb.2012.0021.
50. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30:2068-2069. https://doi.org/10.1093/bioinformatics/btu153.
51. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. J Mol Biol 215:403-410. https://doi.org/10.1016/ S0022-2836(05)80360-2.
52. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754-1760. https://doi.org/10.1093/bioinformatics/btp324.
53. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup. 2009. The sequence alignment/map format and SAMtools. Bioinformatics 25:2078-2079. https://doi.org/10.1093/bioinformatics/btp352.
54. Kern WV, Steinke P, Schumacher A, Schuster S, von Baum H, Bohnert JA. 2006. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chemother 57:339-343. https://doi.org/10.1093/jac/dki445.